GlaxoSmithKline PLC’s new drug approvals in core areas demonstrate the big pharma is delivering on its R&D promises and establishing near-term sales, CEO Andrew Witty said during the company’s third quarter sales and earnings call Oct. 23. But a bribery scandal in China overshadowed any positive news.
Signs Of R&D Progress For GSK, Though China Overhang Remains
With four new drug approvals notched under its belt in four months, GlaxoSmithKline had several potential growth drivers to highlight during its third quarter earnings call, helping to deflect attention away from the bribery scandal in China.